Business News: The Indian stock market on Friday recorded a huge ripen without US President Donald Trump's utterance of imposing 100% tariffs on the import of branded and patent drugs from 1 October. The BSE Sensex fell over 800 points to 80,400 levels during trading. Finally, the Sensex sealed at 80,426.46 points, unthriving 733.22 points, or 0.90%. At the same time, the Nifty 50 moreover fell 238.35 points i.e. 0.96% to tropical at 24,652.50 points.
The most impact on the pharma sector
After Trump's decision, the most pressure was seen in the shares of Indian pharma companies. The Nifty Pharma fell 590 points or 2.7% to the lowest level of the day of 21,390.25. Of the 20 shares of this sector, 17 were in red mark. Large shares like Laus Labs, Biocon, Zayadas LifeSyins and Natco Pharma have fallen by up to 7%. Investors considered it a negative sign.
Continuous ripen throughout the week
The stock market was under pressure this week in the sixth subsequent season. The Sensex has fallen increasingly than 1,850 points from Monday to Friday. The Nifty 50 has moreover wrenched well-nigh 600 points this week. According to experts, besides the US tariff decision, the selling of foreign institutional investors was moreover the main rationalization of pressure in the market.
Pressure in global markets
On Friday, Asian markets moreover saw a fall pressure. Japan's Nikkei was 0.9%, Hong Kong's Hang Seng 1.4% and China's Shanghai Composite was 0.7% below. Heavy selling of foreign investors was moreover unauthentic on the domestic market. On Thursday, FIIS sold shares worth Rs 4,995.42 crore. So far in September, he has sold domestic shares worth Rs 13,450 crore and so far in the year 2025, Rs 1,44,085 crore.
Opinion of experts
Financial analysts say Trump's tariff visualization has unauthentic the global sales and benefits of Indian pharma companies. This increased the fear of foreign investors and unfurled selling in the market.
